BBIO vs PRAX vs ACAD vs RARE

For growth investors, BridgeBio Pharma, Inc.

(BBIO) is the stronger pick with 126. 3% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate BridgeBio Pharma, Inc. (BBIO) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, BridgeBio Pharma, Inc.

(BBIO) delivered a total return of +40. 4%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: BBIO returned +144. 6% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.

(ACAD) is the lower-risk stock at 1. 11β versus Praxis Precision Medicines, Inc. 's 1. 40β — meaning PRAX is approximately 26% more volatile than ACAD relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 4% for ACADIA Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BridgeBio Pharma, Inc.

(BBIO) is pulling ahead at 126. 3% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, BBIO leads at 86. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -145. 3% for BridgeBio Pharma, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -113. 3% for BBIO. At the gross margin level — before operating expenses — BBIO leads at 94. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RARE: 85.

1% to $48. 36.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, BridgeBio Pharma, Inc.

(BBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21), +144. 6% 10Y return). Both have compounded well over 10 years (BBIO: +144. 6%, PRAX: -20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BBIO is a mid-cap high-growth stock; PRAX is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.